Print

Presentation Of Vical Incorporated (VICL)'s Allovectin® Phase 3 Results Scheduled At Society For Melanoma Research Meeting  
11/18/2013 11:28:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that Robert H.I. Andtbacka, M.D., C.M., will present detailed results from the completed Phase 3 trial of Allovectin® (velimogene aliplasmid) at 4:45 p.m. EST today, November 18, at the 10th International Meeting of the Society for Melanoma Research (Philadelphia, PA – November 17-20). Dr. Andtbacka, a surgeon and investigator with the Huntsman Cancer Institute at the University of Utah School of Medicine, was a principal investigator of the Phase 3 trial. A copy of today's presentation will be posted on the Events page in the Investors section of the Vical website at www.vical.com at the time of the live presentation.

Help employers find you! Check out all the jobs and post your resume.

//-->